Anticoagulation Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Warfarin, Heparin, Novel Oral Anticoagulants, Others), By Route of Administration (Oral, Parenteral), By Application (Therapeutic applications, Laboratory Services), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region  

Anticoagulation Therapy Market size was valued at US$ 24,732.3 million in 2023 and is poised to grow at a significant CAGR of 7.8% from 2024-2030. The global market provides a detailed overview of the market size, and that can be segmented by drug type, by route of administration, by application, and by Distribution channel. By drug type, the market growth has been segmented into Warfarin, Heparin, Novel Oral Anticoagulants, and Others. The Novel oral anticoagulants (NOACs) segment is likely to be the largest and fastest-growing segment in terms of drug type. T Novel oral anticoagulants (NOACs) are a new type of anticoagulant drug.

Furthermore, these are safe as a lower frequency of excessive bleeding is recorded, are suitable to use, have no reactions to food, and have a brief half-life. Some of the NOACs comprise dabigatran, apixaban, rivaroxaban, and edoxaban. These can be used in the stoppage and cure of atrial fibrillation or myocardial infarction, pulmonary embolism, and deep vein thrombosis (DVT).  Based on the Route of administration, the market is segmented into Oral, Parenteral. Among these, the Oral route of administration segment is expected to have the fastest-growing market during the forecast period 2022-2028. Oral anticoagulants are expected to generate the highest market revenue during the forecast period. Oral anticoagulants are one of the most traditional and standard modes of administration of anticoagulant therapy, and they are expected to expand during the forecast period. The oral anticoagulants segment is further expected to grow as there are many prominent product launches.

Due to technological advancements in anticoagulants and their influence on a considerable reduction in risk, this segment is further expected to increase the global anticoagulant market growth. Based on application, the market is segmented into Therapeutic applications, Clinical Laboratory Services. Among these, the Therapeutic applications segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on the Distribution channel, the Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment is expected to have a significant share in 2021.

Anticoagulation Therapy Market Key Developments

• In June 2021, US FDA approved Pradaxa first oral anticoagulant to cure children aged 3 months to less than 12 years old with venous thromboembolism after they have obtained at least five days of treatment with a blood thinner given by injection.
• In February 2022, US FDA granted the fast track of Bayers oral Factor Xia inhibitor Asundexian